LC
IMDX

Lindbrook Capital’s Insight Molecular Diagnostics IMDX Stock Holding History

Lindbrook Capital’s Portfolio IMDX Stock Details IMDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-4
Closed -$10 – 2725
2023
Q4 		$10 Hold
4
– – ﹤0.01% 2685
2023
Q3 		$12 Hold
4
– – ﹤0.01% 2679
2023
Q2 		$20 Hold
4
– – ﹤0.01% 2691
2023
Q1 		$30 Hold
4
– – ﹤0.01% 2753
2022
Q4 		$28 Hold
4
– – ﹤0.01% 2802
2022
Q3 		$0 Hold
4
– – ﹤0.01% 2825
2022
Q2 		$0 Hold
4
– – ﹤0.01% 2678
2022
Q1 		$0 Hold
4
– – ﹤0.01% 2574
2021
Q4 		$0 Sell
4
-6
-60% -$345 ﹤0.01% 2171
2021
Q3 		$1K Buy
+10
New +$919 ﹤0.01% 1756

Other funds holding IMDX

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DC
Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Lindbrook Capital's IMDX Position: Q1 2024 in Review

Lindbrook Capital sold out of Insight Molecular Diagnostics (IMDX) in Q1 2024, closing a stake of 4 shares — an estimated $10 sold.

Lindbrook Capital first reported a position in IMDX in Q3 2021 and held it in 10 quarters. The position peaked at $1K in Q3 2021. 25 funds tracked by Wall St. Rank hold IMDX as of Q1 2024.

  • Lindbrook Capital reported no remaining Insight Molecular Diagnostics position as of Q1 2024 after selling out during the quarter.
  • Lindbrook Capital sold 4 Insight Molecular Diagnostics shares in Q1 2024, an estimated $10.
  • Lindbrook Capital first reported a position in Insight Molecular Diagnostics in Q3 2021 and held it in 10 quarters.
  • Lindbrook Capital's Insight Molecular Diagnostics position peaked at $1K in Q3 2021.
  • 25 funds tracked by Wall St. Rank held Insight Molecular Diagnostics as of Q1 2024.

Based on Lindbrook Capital's 13F filing for Q1 2024, filed 25 Apr 2024.